The company was founded by experienced pharmaceutical executives to develop and commercialize therapeutics in areas of significant unmet medical need. Ception's portfolio includes treatments for central nervous system disorders, pain, and cancer, and it offers Reslizumab for eosinophilic inflammatory conditions. The company also provides Anti-TNF, a class of small molecule anti-TNF receptor agents with the potential to be orally administered. Cephalon's research pipeline is focused on developing new compounds and new indications for existing products, while their business collaborations capitalize on new products and smart drug delivery technologies.